Phil Nadeau, Ph.D.

Managing Director, Health Care - Biotechnology

Headshot photo of Phil Nadeau

Philip Nadeau is a managing director and senior research analyst on the biotechnology team at Cowen. He joined Cowen in 2000 and is responsible for covering approximately 25 large-, mid-, and small-cap biotechnology stocks. Cowen’s biotechnology team has consistently been among the top-ranked teams in the Greenwich Survey. Dr. Nadeau has been recognized in The Wall Street Journal’s “Best on the Street” rankings and in the Institutional Investor poll. His views on biotechnology topics are often quoted by national news services such as Reuters, Bloomberg and the Dow Jones newswires. Prior to joining Cowen, he was a research assistant at Children’s Hospital, Boston.

Dr. Nadeau has an SB/MEng in electrical engineering and computer science from MIT and a Ph.D. in Neurobiology from Harvard University. 

Get In Touch

Start a conversation with Phil Nadeau

    Insights

    Explore related thought leadership, reports, coverage and insights for Phil Nadeau.

    Medical researcher conducting pharmaceutical research in a lab. Representing innovative therapies for fighting cancer i.e., immuno-oncology
    Ahead of the Curve®

    Investors Guide to Immuno-Oncology

    Ahead of the Curve®

    5th Annual Investor Primer on Antibody Drug Conjugates

    Best ESG Investment Ideas for 2023